Vaccine escape in a heterogeneous population: insights for SARS-CoV-2 from a simple model

Author:

Gog Julia R.12ORCID,Hill Edward M.2345ORCID,Danon Leon267ORCID,Thompson Robin N.234ORCID

Affiliation:

1. Department of Applied Mathematics and Theoretical Physics, University of Cambridge, Cambridge, UK

2. JUNIPER – Joint UNIversities Pandemic and Epidemiological Research, UK

3. The Zeeman Institute for Systems Biology and Infectious Disease Epidemiology Research, University of Warwick, Coventry, UK

4. Mathematics Institute, University of Warwick, Coventry, UK

5. School of Life Sciences, University of Warwick, Coventry, UK

6. Department of Engineering Mathematics, University of Bristol, Bristol, UK

7. The Alan Turing Institute, London, UK

Abstract

As a countermeasure to the SARS-CoV-2 pandemic, there has been swift development and clinical trial assessment of candidate vaccines, with subsequent deployment as part of mass vaccination campaigns. However, the SARS-CoV-2 virus has demonstrated the ability to mutate and develop variants, which can modify epidemiological properties and potentially also the effectiveness of vaccines. The widespread deployment of highly effective vaccines may rapidly exert selection pressure on the SARS-CoV-2 virus directed towards mutations that escape the vaccine-induced immune response. This is particularly concerning while infection is widespread. By developing and analysing a mathematical model of two population groupings with differing vulnerability and contact rates, we explore the impact of the deployment of vaccines among the population on the reproduction ratio, cases, disease abundance and vaccine escape pressure. The results from this model illustrate two insights: (i) vaccination aimed at reducing prevalence could be more effective at reducing disease than directly vaccinating the vulnerable; (ii) the highest risk for vaccine escape can occur at intermediate levels of vaccination. This work demonstrates a key principle: the careful targeting of vaccines towards particular population groups could reduce disease as much as possible while limiting the risk of vaccine escape.

Funder

UK Research and Innovation

Publisher

The Royal Society

Subject

Multidisciplinary

Reference48 articles.

1. World Health Organization. 2021 Coronavirus disease (COVID-19) weekly epidemiological update – 9 March 2021. www.who.int/docs/default-source/coronaviruse/situation-reports/20210309_weekly_epi_update_30.pdf (accessed 12 March 2021).

2. London School of Hygiene & Tropical Medicine. 2021 COVID-19 vaccine tracker – Living review. https://vac-lshtm.shinyapps.io/ncov_vaccine_landscape/ (accessed 12 March 2021).

3. Safety and Efficacy of the BNT162b2 mRNA Covid-19 Vaccine

4. Efficacy and Safety of the mRNA-1273 SARS-CoV-2 Vaccine

5. Public Health England. 2021 Investigation of SARS-CoV-2 variants of concern in England: Technical briefing 6. https://assets.publishing.service.gov.uk/government/uploads/system/uploads/attachment_data/file/961299/Variants_of_Concern_VOC.Technical_Briefing_6_England-1.pdf (accessed 12 March 2021).

同舟云学术

1.学者识别学者识别

2.学术分析学术分析

3.人才评估人才评估

"同舟云学术"是以全球学者为主线,采集、加工和组织学术论文而形成的新型学术文献查询和分析系统,可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容,当前同舟云学术共收录了国内外主流学术期刊6万余种,收集的期刊论文及会议论文总量共计约1.5亿篇,并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询!咨询电话:010-8811{复制后删除}0370

www.globalauthorid.com

TOP

Copyright © 2019-2024 北京同舟云网络信息技术有限公司
京公网安备11010802033243号  京ICP备18003416号-3